Identification of Four New Chemical Series of Small Drug‐Like Natural Products as Potential Neuropilin‐1 Inhibitors by Structure‐Based Virtual Screening: Pharmacophore‐Based Molecular Docking and Dynamics Simulation

Abstract

AbstractNeuropilin‐1 (NRP‐1), a surface transmembrane glycoprotein, is one of the most important co‐receptors of VEGF‐A165 (vascular endothelial growth factor) responsible for pathological angiogenesis. In general, NRP‐1 overexpression in cancer correlates with poor prognosis and more tumor aggressiveness. NRP‐1 role in cancer has been mainly explained by mediating VEGF‐A165‐induced effects on tumor angiogenesis. NRP‐1 was recently identified as a co‐receptor and an independent gateway for SARS‐CoV‐2 through binding subunit S2 of Spike protein in the same way as VEGF‐A165. Thus, NRP‐1 is of particular value as a target for cancer therapy and other angiogenesis‐dependent diseases as well as for SARS‐CoV‐2 antiviral intervention. Herein, The Super Natural II, the largest available database of natural products (∼0.33 M), pre‐filtered with drug‐likeness criteria (absorption, distribution, metabolism and excretion/toxicity), was screened against NRP‐1. NRP‐1/VEGF‐A165 interaction is one of protein‐protein interfaces (PPIs) known to be challenging when approached in‐silico. Thus, a PPI‐suited multi‐step virtual screening protocol, incorporating a derived pharmacophore with molecular docking and followed by MD (molecular dynamics) simulation, was designed. Two stages of pharmacophorically constrained molecular docking (standard and extra precisions), a mixed Torsional/Low‐mode conformational search and MM‐GBSA ΔG binding affinities calculation, resulted in the selection of 100 hits. These 100 hits were subjected to 20 ns MD simulation, that was extended to 100 ns for top hits (20) and followed by post‐dynamics analysis (atomic ligand‐protein contacts, RMSD, RMSF, MM‐GBSA ΔG, Rg, SASA and H‐bonds). Post‐MD analysis showed that 19 small drug‐like nonpeptide natural molecules, grouped in four chemical scaffolds (purine, thiazole, tetrahydropyrimidine and dihydroxyphenyl), well verified the derived pharmacophore and formed stable and compact complexes with NRP‐1. The discovered molecules are promising and can serve as a base for further development of new NRP‐1 inhibitors.